copyright 2002 pfizer inc internet2 & pharma industry national priorities for transforming...
Post on 26-Dec-2015
218 Views
Preview:
TRANSCRIPT
Copyright 2002 Pfizer Inc
Internet2 & Pharma IndustryNational Priorities for Transforming Healthcare Quality Report - implications for patient safety and internet applications
Ernest T. AndalcioExecutive Director, Site Head Informatics
Pfizer Global Research & DevelopmentApril 10, 2003
Copyright 2002 Pfizer Inc
Intro
Ernest Andalcio - Executive Director - Ann Arbor Labs
With Pfizer for 5 years before that Bristol-Myers Squibb, Johnson & Johnson
and Procter & Gamble Responsible for mobilizing the talents of IT staff
to identify, design, develop and implement robust technology solutions enabling delivery of scientific excellence, and for promoting best practices, fostering IT knowledge-sharing and exploring innovative new technologies
Copyright 2002 Pfizer Inc
Topics/Contents
Pharmaceutical Industry Challenges Opportunities Learnings
Copyright 2002 Pfizer Inc
Pfizer Research & Development Largest privately funded biomedicalresearch organization
Seven major research sites
2002 R & D investment of $5.3 billion
Count on a few new medicines to reachthe market each year
4 filings planned for 2003
Target of 20 filings in next 5 years
Mission…”We will be the most consistently productive R&D organization in the industry.”
Copyright 2002 Pfizer Inc
Topics/Contents
Pharmaceutical Industry Challenges Opportunities Learnings
Copyright 2002 Pfizer Inc
Challenges in our Industry
Balancing Patient needs Medicine Patents New Regulations Profitability Risk Social responsibility Shareholder expectations
Copyright 2002 Pfizer Inc
Clinical Trials Require More Patients
35674237
5779
1321
1981-84 1989-92 1994-95 1998-2000
35674237
5779
1321
1981-84 1989-92 1994-95 1998-2000
Source: Parexel Pharmaceutical R&D Statistical Sourcebook 2001; Centerwatch, An Industry in Evolution 2001
Worldwide Industry Number of Patients per NCEWorldwide Industry Number of Patients per NCE
Copyright 2002 Pfizer Inc
Challenges - the long road to a new medicine & how Internet2solutions could one-day help the process
Discovery
Exploratory Development
Full Development
Registration
Copyright 2002 Pfizer Inc
Most
Compounds
Do Not Become
Medicines
Most
Compounds
Do Not Become
Medicines
Challenges - R&D Attrition (why new chemical entities
fail)
Complex Disease Targets
Impractical To Make
Not Sufficiently
Selective
Competition
Unsafe
Poor Absorption
Low Levels in Body Unstable
Adverse Reactions
Not Effective Enough
Side Effects
Too Long in Body
Copyright 2002 Pfizer Inc
Pharmaceutical Technology in Action
Gather, analyze and present valuable and timely information to therapeutic project teams for high-priority targets.
Use information to help identify novel, high quality targets that may be pursued by the therapeutic project teams.
Data Mining Sequence Analysis Information Storage/Retrieval (Database) Information Presentation
Copyright 2002 Pfizer Inc
The Challenge…
Biology: The Target
• Select the disease-related protein• Understand its function and role
Biology: The Target
• Select the disease-related protein• Understand its function and role
Chemistry: The Compound
• Optimize the potency• Avoid adverse pharmacokinetics• Avoid adverse toxic effects
Chemistry: The Compound
• Optimize the potency• Avoid adverse pharmacokinetics• Avoid adverse toxic effects
Copyright 2002 Pfizer Inc
Topics/Contents
Pharmaceutical Industry Challenges Opportunities Learnings
Copyright 2002 Pfizer Inc
Opportunities - The Future of Medicine
Freedom from heart disease
A full, normal life for diabetics
Preserving the antibiotic miracle
Taking the fear out of cancer
Eliminating frailty in the elderly
Preventing Alzheimer’s disease
Copyright 2002 Pfizer Inc
Opportunities - The Future of Medicine
Cardiovascular Disease
HIV/AIDs
Urogenital
Pulmonary
Central Nervous System
Diabetes
Women’s Health
20 new filings in next 5 years
Copyright 2002 Pfizer Inc
Opportunities - Pharma Informatics Increase productivity
Seek different ways of working to increase the number of medicines that make it to full development annually
Enable new business processes: Improve data/information for timely decision-making
Leverage Scale Take advantage of Global Capacity Maximize use of Best Practices: Quality and
Architecture of systems used
Copyright 2002 Pfizer Inc
Topics/Contents
Pharmaceutical Industry Challenges Opportunities Learnings
Copyright 2002 Pfizer Inc
Learnings - Opportunities for Internet2 to make
it happen
Due to the nature of our business - research - enabling technologies like Internet2 aid internal global execution of the R&D process E.g. “Flipping through” large, secure files (e.g. x-ray
images) to spot changes in size of tumors Pfizer does global R&D, however, due to the
nature of our business – highly proprietary – it is a largely secure intranet environment: though we accept information from outside
vendors using “safe zones” technologies
Copyright 2002 Pfizer Inc
Learnings - Opportunities for Internet2 to make it happen
Enabling new business processes Streamlined Discovery & Development
processes Improved data/information for more timely
(real-time) decision-making (Hi bandwidth human interactions! “Charles Yun”)
First-time Better Earlier
Enabling Digital Science “David G. Messerschmidt”
Copyright 2002 Pfizer Inc
Summary
Pharma Industry (Challenges/Opportunities) Pharmaceutical R&D processes Internet2… can enable real-time analysis,
dialogue and … “discovery” of new medicines
top related